Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful ...

Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients ...

Data presented at this year’s American Heart Association Scientific Sessions in New Orleans underline rapid advancements in ...

The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical ...

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

The Dow Jones (DJIA) is trading in positive territory on Tuesday, while both the S&P 500 (SPX) and the Nasdaq 100 (NDX) are ...

Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as ...

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.

The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...

Despite President Trump’s claims, scientists don’t have enough evidence to say acetaminophen use during pregnancy is linked ...

GoodRx Holdings, Inc. ( GDRX) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx Third Quarter 2025 Earnings Call. As a ...